CLDX - Celldex Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 534.84M
Enterprise Value 3-42.09M
Trailing P/E N/A
Forward P/E 1-0.69
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)7.19
Price/Book (mrq)0.31
Enterprise Value/Revenue 3-8.69
Enterprise Value/EBITDA 60.82

Trading Information

Stock Price History

Beta (3Y Monthly) 4.20
52-Week Change 3-66.94%
S&P500 52-Week Change 30.90%
52 Week High 311.5500
52 Week Low 32.0100
50-Day Moving Average 32.3000
200-Day Moving Average 33.6199

Share Statistics

Avg Vol (3 month) 3209.79k
Avg Vol (10 day) 3200.56k
Shares Outstanding 5162.44M
Float 14.08M
% Held by Insiders 10.36%
% Held by Institutions 128.30%
Shares Short (Jul 31, 2019) 41.19M
Short Ratio (Jul 31, 2019) 410.6
Short % of Float (Jul 31, 2019) 49.21%
Short % of Shares Outstanding (Jul 31, 2019) 47.93%
Shares Short (prior month Jun 28, 2019) 41.23M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 215/1
Last Split Date 3Feb 11, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,143.10%

Management Effectiveness

Return on Assets (ttm)-21.59%
Return on Equity (ttm)-38.43%

Income Statement

Revenue (ttm)4.84M
Revenue Per Share (ttm)0.40
Quarterly Revenue Growth (yoy)-74.10%
Gross Profit (ttm)-55.91M
EBITDA -51.31M
Net Income Avi to Common (ttm)-45.66M
Diluted EPS (ttm)-3.7410
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)81.34M
Total Cash Per Share (mrq)5.42
Total Debt (mrq)4.41M
Total Debt/Equity (mrq)4.02
Current Ratio (mrq)7.33
Book Value Per Share (mrq)7.40

Cash Flow Statement

Operating Cash Flow (ttm)-54.09M
Levered Free Cash Flow (ttm)-32.31M